Skip to main
TMCI

TMCI Stock Forecast & Price Target

TMCI Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 20%
Buy 0%
Hold 60%
Sell 20%
Strong Sell 0%

Bulls say

Treace Medical Concepts Inc. has demonstrated a year-over-year increase of 7.0% in active surgeon users, totaling approximately 3,285, which reflects a solid foundation for growth despite a slight decline in utilization per surgeon. The company has strategically expanded its product offerings beyond the Lapiplasty system to address the competitive landscape, creating opportunities for modest revenue growth and improved margins through higher average selling prices and increased market share in complementary procedures. Additionally, the enhancement of the sales force and initiatives to boost direct-to-consumer programs, physician education, and sales rep hiring are positioned to capitalize on the anticipated recovery of the bunion market, providing a positive outlook for Treace Medical Concepts's financial performance.

Bears say

Treace Medical Concepts Inc. is facing a challenging financial outlook, as projected revenue for the fourth quarter is anticipated to decline by approximately 10% year-over-year to $61.8 million, despite traditionally being a peak period for bunion procedures. The company's revenue guidance for FY25 has been revised down from $224-230 million to $211-213 million, primarily due to headwinds related to lapiplasty and a slowdown in elective surgeries, leading to further concerns about the sustainability of its growth. Additionally, customer feedback indicates an average decline in bunion procedure volumes of around 7% year-over-year, suggesting ongoing pressure on the company's market demand and future revenue potential.

TMCI has been analyzed by 5 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 0% recommend Buy, 60% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Treace Medical Concepts (TMCI) Forecast

Analysts have given TMCI a Hold based on their latest research and market trends.

According to 5 analysts, TMCI has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Treace Medical Concepts (TMCI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.